HRP20170098T1 - Derivati pirazola i njihova uporaba kao antagonista lpar5 - Google Patents
Derivati pirazola i njihova uporaba kao antagonista lpar5 Download PDFInfo
- Publication number
- HRP20170098T1 HRP20170098T1 HRP20170098TT HRP20170098T HRP20170098T1 HR P20170098 T1 HRP20170098 T1 HR P20170098T1 HR P20170098T T HRP20170098T T HR P20170098TT HR P20170098 T HRP20170098 T HR P20170098T HR P20170098 T1 HRP20170098 T1 HR P20170098T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- group
- cycloalkyl
- unsubstituted
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305552 | 2012-05-18 | ||
| PCT/EP2013/060171 WO2013171317A1 (en) | 2012-05-18 | 2013-05-16 | Pyrazole derivatives and their use as lpar5 antagonists |
| EP13723151.0A EP2882715B1 (en) | 2012-05-18 | 2013-05-16 | Pyrazole derivatives and their use as lpar5 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170098T1 true HRP20170098T1 (hr) | 2017-03-24 |
Family
ID=48446368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170098TT HRP20170098T1 (hr) | 2012-05-18 | 2013-05-16 | Derivati pirazola i njihova uporaba kao antagonista lpar5 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9346762B2 (enExample) |
| EP (1) | EP2882715B1 (enExample) |
| JP (1) | JP6257596B2 (enExample) |
| KR (1) | KR20150010973A (enExample) |
| CN (1) | CN104302625B (enExample) |
| AU (1) | AU2013261718B2 (enExample) |
| BR (1) | BR112014028406A2 (enExample) |
| CA (1) | CA2871542A1 (enExample) |
| CY (1) | CY1118618T1 (enExample) |
| DK (1) | DK2882715T3 (enExample) |
| ES (1) | ES2612205T3 (enExample) |
| HR (1) | HRP20170098T1 (enExample) |
| HU (1) | HUE032890T2 (enExample) |
| IL (1) | IL235221A (enExample) |
| LT (1) | LT2882715T (enExample) |
| MX (1) | MX347615B (enExample) |
| PL (1) | PL2882715T3 (enExample) |
| PT (1) | PT2882715T (enExample) |
| RU (1) | RU2645344C2 (enExample) |
| SG (1) | SG11201407210SA (enExample) |
| SI (1) | SI2882715T1 (enExample) |
| WO (1) | WO2013171317A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013171316A1 (en) | 2012-05-18 | 2013-11-21 | Sanofi | Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation |
| WO2016201426A1 (en) | 2015-06-12 | 2016-12-15 | Vettore, LLC | Mct4 inhibitors for treating disease |
| DK3551625T3 (da) * | 2016-12-12 | 2024-09-02 | Vettore Llc | Heterocykliske inhibitorer af mct4 |
| WO2024092205A1 (en) * | 2022-10-27 | 2024-05-02 | The Trustees Of Indiana University | Inhibition of ship1 as a therapeutic strategy for the treatment of alzheimer's disease |
| CN119930520A (zh) * | 2023-11-03 | 2025-05-06 | 中国药科大学 | N-芳基吡唑类化合物及其药物组合物和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1230441B (it) | 1989-02-07 | 1991-10-23 | Acraf | Eteri della serie dell'indazolo |
| JP4505329B2 (ja) | 2002-09-04 | 2010-07-21 | メルク フロスト カナダ リミテツド | カテプシンシステインプロテアーゼ阻害薬 |
| KR20090106660A (ko) | 2007-02-09 | 2009-10-09 | 다케다 야쿠힌 고교 가부시키가이샤 | Ｐｐａｒ-감마의 부분 작용제로서의 축합 고리 화합물 |
| JP5560202B2 (ja) | 2007-12-26 | 2014-07-23 | サノフイ | Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体 |
| BRPI0907977A2 (pt) * | 2008-03-07 | 2015-08-04 | Acraf | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças |
| JP5509100B2 (ja) | 2008-03-07 | 2014-06-04 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体及びそのＭＣＰ−１，ＣＸ３ＣＲ１及びｐ４０の発現に基づく疾病の治療への使用 |
| US20120010241A1 (en) * | 2009-03-19 | 2012-01-12 | Sanofi | Hsp90 inhibiting indazole derivatives, compositions containing same and use thereof |
| US8350052B2 (en) * | 2009-08-03 | 2013-01-08 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Process for the preparation of 1-benzyl-3-hydroxymethyl-1H-indazole and its derivatives and required magnesium intermediates |
| JP6039559B2 (ja) * | 2010-09-02 | 2016-12-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｌｐａ受容体アンタゴニストとしてのピラゾロピリジノン誘導体 |
| WO2013171316A1 (en) | 2012-05-18 | 2013-11-21 | Sanofi | Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation |
-
2013
- 2013-05-16 HU HUE13723151A patent/HUE032890T2/hu unknown
- 2013-05-16 HR HRP20170098TT patent/HRP20170098T1/hr unknown
- 2013-05-16 JP JP2015512072A patent/JP6257596B2/ja not_active Expired - Fee Related
- 2013-05-16 SI SI201330499A patent/SI2882715T1/sl unknown
- 2013-05-16 DK DK13723151.0T patent/DK2882715T3/en active
- 2013-05-16 US US14/401,050 patent/US9346762B2/en not_active Expired - Fee Related
- 2013-05-16 WO PCT/EP2013/060171 patent/WO2013171317A1/en not_active Ceased
- 2013-05-16 SG SG11201407210SA patent/SG11201407210SA/en unknown
- 2013-05-16 BR BR112014028406A patent/BR112014028406A2/pt not_active Application Discontinuation
- 2013-05-16 ES ES13723151.0T patent/ES2612205T3/es active Active
- 2013-05-16 AU AU2013261718A patent/AU2013261718B2/en not_active Ceased
- 2013-05-16 KR KR20147033843A patent/KR20150010973A/ko not_active Ceased
- 2013-05-16 PT PT137231510T patent/PT2882715T/pt unknown
- 2013-05-16 MX MX2014014011A patent/MX347615B/es active IP Right Grant
- 2013-05-16 CN CN201380025967.9A patent/CN104302625B/zh not_active Expired - Fee Related
- 2013-05-16 EP EP13723151.0A patent/EP2882715B1/en not_active Not-in-force
- 2013-05-16 CA CA2871542A patent/CA2871542A1/en not_active Abandoned
- 2013-05-16 RU RU2014151360A patent/RU2645344C2/ru not_active IP Right Cessation
- 2013-05-16 LT LTEP13723151.0T patent/LT2882715T/lt unknown
- 2013-05-16 PL PL13723151T patent/PL2882715T3/pl unknown
-
2014
- 2014-10-20 IL IL235221A patent/IL235221A/en active IP Right Grant
-
2017
- 2017-02-08 CY CY20171100175T patent/CY1118618T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201407210SA (en) | 2014-12-30 |
| IL235221A (en) | 2016-06-30 |
| US9346762B2 (en) | 2016-05-24 |
| RU2014151360A (ru) | 2016-07-10 |
| BR112014028406A2 (pt) | 2017-06-27 |
| SI2882715T1 (sl) | 2017-03-31 |
| CN104302625B (zh) | 2017-04-19 |
| AU2013261718B2 (en) | 2017-10-19 |
| MX347615B (es) | 2017-05-04 |
| WO2013171317A1 (en) | 2013-11-21 |
| JP2015517514A (ja) | 2015-06-22 |
| AU2013261718A1 (en) | 2014-12-18 |
| CN104302625A (zh) | 2015-01-21 |
| EP2882715A1 (en) | 2015-06-17 |
| LT2882715T (lt) | 2017-02-10 |
| RU2645344C2 (ru) | 2018-02-21 |
| CA2871542A1 (en) | 2013-11-21 |
| PL2882715T3 (pl) | 2017-04-28 |
| HUE032890T2 (hu) | 2017-11-28 |
| JP6257596B2 (ja) | 2018-01-10 |
| MX2014014011A (es) | 2015-02-12 |
| KR20150010973A (ko) | 2015-01-29 |
| EP2882715B1 (en) | 2016-11-09 |
| CY1118618T1 (el) | 2017-07-12 |
| PT2882715T (pt) | 2016-12-30 |
| DK2882715T3 (en) | 2017-02-13 |
| ES2612205T3 (es) | 2017-05-12 |
| US20150141477A1 (en) | 2015-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170098T1 (hr) | Derivati pirazola i njihova uporaba kao antagonista lpar5 | |
| Wood et al. | Systemic hypoxia increases leukocyte emigration and vascular permeability in conscious rats | |
| Jolley et al. | Fontan physiology revisited | |
| Davies et al. | Modified ultrafiltration improves left ventricular systolic function in infants after cardiopulmonary bypass | |
| Götberg et al. | Mild hypothermia reduces acute mortality and improves hemodynamic outcome in a cardiogenic shock pig model | |
| Aneman et al. | Advances in critical care management of patients undergoing cardiac surgery | |
| JP2004532250A (ja) | 線維性疾患又は他の適応症の治療方法 | |
| JP2013531028A5 (enExample) | ||
| Kartha et al. | Laparoscopic cholecystectomy in a patient with an implantable left ventricular assist device | |
| Margulies et al. | Sulfinpyrazone: a review of its pharmacological properties and therapeutic use | |
| RU2008143703A (ru) | ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА | |
| JP2015517514A5 (enExample) | ||
| KR102489989B1 (ko) | 체외 지원을 위한 시스템 및 방법 | |
| JP2015521183A5 (enExample) | ||
| CA3137138A1 (en) | Methods of treating hypertension with activators of tie-2 | |
| WO2006045756A1 (en) | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | |
| CN105358148A (zh) | 用于治疗肾小球疾病的losmapimod | |
| Loeffelbein et al. | High colloid oncotic pressure priming of cardiopulmonary bypass in neonates and infants: implications on haemofiltration, weight gain and renal function | |
| Bendel et al. | Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation | |
| CN100398104C (zh) | 抗血栓药和吡唑啉酮衍生物的组合药物 | |
| Izumi et al. | The efficacy of human atrial natriuretic peptide in patients with renal dysfunction undergoing cardiac surgery | |
| PT1874745E (pt) | Novos derivados de ácido 3-fenilpropiónico e seu uso como ligandos receptores de ppar-gama | |
| JP2020529396A5 (enExample) | ||
| Jha et al. | Newer oral anticoagulant in chronic kidney disease: what we should know | |
| Song et al. | Effect of preoperative statin therapy on myocardial protection and morbidity endpoints following off-pump coronary bypass surgery in patients with elevated C-reactive protein level |